International Clinical Trial: DEMEL-1: A single-center, single-arm, phase II clinical study evaluating the efficacy and safety of Decitabine combined with low-dose Melphalan in patients with high-risk refractory myelodysplastic syndrome

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115432) titled 'DEMEL-1: A single-center, single-arm, phase II clinical study evaluating the efficacy and safety of Decitabine combined with low-dose Melphalan in patients with high-risk refractory myelodysplastic syndrome' on Dec. 25, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

Condition: Meet the diagnostic criteria for Myelodysplastic Syndromes (MDS) according to the WHO-2022 classification of myeloid neoplasms and meet the definition of refractory higher-risk MDS: patients who have not achieved hematologic impro...